状神经营因子的重组变体用于肥胖成年人减肥:一个随机的,剂量范围研究
Mark P Ettinger1, Thomas W Littlejohn, Sherwyn L Schwartz
1Radiant Research, Stuart, Fla, USA.
JAMA
|April 10, 2003
概括
再组合的人类变异状神经变因子 (rhvCNTF) 在肥胖的成年人中显示出显著的体重减轻,绕过了白素抵抗. 需要进一步的试验来证实这些有希望的初步发现,用于治疗肥胖症.
科学领域:
- 肥胖研究的研究.
- 代谢障碍 代谢障碍 代谢障碍
- 药理干预措施 药理干预措施
背景情况:
- 肥胖个体通常会对莱普的体重调节效果表现出抵抗力.
- 重组的人类变异神经营养因子 (rhvCNTF) 显示出通过类似途径发出信号来克服瘦素耐药性的潜力.
- 以前的动物研究表明,rhvCNTF可以在肥胖模型中绕过瘦素抵抗.
研究的目的:
- 确定rhvCNTF的安全和耐受剂量,用于诱导肥胖成人的体重减轻.
- 评估rhvCNTF在临床环境中的有效性,以控制体重.
主要方法:
- 一个为期12周的双盲随机多中心临床试验,涉及173名肥胖成年人.
- 参与者每天接受安慰剂或不同剂量的rhvCNTF (0.3,1.0或2.0微克/公斤) 的皮下注射.
- 体重变化和实现至少5%体重减轻的患者比例是主要结果指标,与低热量饮食干预一起.
主要成果:
- 与安慰剂相比,rhvCNTF治疗导致了统计学上显著的体重减轻 (P<.001趋势).
- 在1.0微克/公斤和2.0微克/公斤的rhvCNTF组中,体重减轻最为显著,分别为29.6%和26%的患者实现了≥5%的体重减轻.
- rhvCNTF通常耐受良好,不良事件以剂量相关的方式发生,主要是轻度注射部位反应.
结论:
- 这一初始剂量范围研究表明,rhvCNTF有效地促进肥胖成人的体重减轻.
- 这些发现表明rhvCNTF是肥胖的潜在治疗剂,需要进一步调查.
- 需要进行更大规模的前性临床试验来验证这些初步结果,并确认rhvCNTF的长期安全性和有效性.
更多相关视频
06:28A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
2.1K
06:16White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
Published on: September 9, 2025
669
相关概念视频
01:24Obesity
1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
01:13Bioequivalence studies: Biowaivers
433
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
433
01:21Drug Dosing: Obese Patients
374
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
374
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
448
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
448
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
332
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
332